Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.
Acquired drug resistance prevents cancer therapies from achieving stable and complete responses. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells. The persister cell pool constitutes a reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore presents a therapeutic opportunity to impede tumour relapse. We previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid hydroperoxidase GPX4 for survival. Here we show that a similar therapy-resistant cell state underlies the behaviour of persister cells derived from a wide range of cancers and drug treatments. Consequently, we demonstrate that persister cells acquire a dependency on GPX4. Loss of GPX4 function results in selective persister cell ferroptotic death in vitro and prevents tumour relapse in mice. These findings suggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance.
|Year of Publication
2017 11 09
|PubMed Central ID
U01 CA168370 / CA / NCI NIH HHS / United States
U01 CA176152 / CA / NCI NIH HHS / United States
HHMI / Howard Hughes Medical Institute / United States
U01 CA168397 / CA / NCI NIH HHS / United States
U01 CA217882 / CA / NCI NIH HHS / United States
R01 CA212767 / CA / NCI NIH HHS / United States
U01 CA217848 / CA / NCI NIH HHS / United States